Skip to main content
Fig. 2 | Clinical and Translational Allergy

Fig. 2

From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months

Fig. 2

Evaluation of bronchial eosinophilic infiltration (cells/mm2) in omalizumab responders (OR) and non-omalizumab responders (NOR) using the natural logarithm of the score fold change, (ln[T36/T0]). Negative values indicate a decrease in the eosinophil count at T36; positive values indicate an increase in the eosinophil count at T36. OR and NOR are classified according to whether they experienced a reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatment

Back to article page